Literature DB >> 9795125

The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice.

K Saigoh1, K Matsui, K Takahashi, T Nishikawa, K Wada.   

Abstract

Spinocerebellar ataxia is one of the most common neurological disorders. However, few therapeutics are effective for the treatment of this disorder. In the present study, we investigated the efficacy of d-serine ethylester and a related substance, d-cycloserine, as therapeutic agents for ataxia in a murine model. Both compounds are known to stereospecific modulate N-methyl-d-aspartate type glutamate receptors, and impaired glutamate-mediated signaling has been implicated in spinocerebellar ataxia. Using a microdialysis method, we found that intraperitoneal administration of d-serine ethylester increases the extracellular content of endogenous d-serine in the mouse cerebellum for at least 3 h. Maximum elevation of the extracellular d-serine was observed at 40 min after injection. An open-field study was used to assay the effect of the d-serine derivatives on movement and ataxia. In mice exhibiting cytosine arabinoside-induced ataxia, d-serine ethylester reduced the falling index in a dose-dependent manner. The effect of d-serine ethylester was stereo-specific in that l-serine ethylester had no effect on the falling index at the maximum doses tested, and was partially inhibited by 5,7-dichlorokynurenate, an antagonist that binds to the glycine-binding site. Locomotor activity was not changed by the d-serine ethylester treatment. d-cycloserine also significantly reduced the falling index of the mice. Both d-serine ethylester and d-cycloserine had longer lasting effects than other potential therapeutic reagents for ataxia. Growing evidence suggests the essential involvement of endogenous d-serine in mammalian brain function, and our results suggest that d-serine derivatives may represent an effective new therapeutic for the treatment of spinocerebellar ataxia. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795125     DOI: 10.1016/s0006-8993(98)00810-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Pharmacological treatments of cerebellar ataxia.

Authors:  Masafumi Ogawa
Journal:  Cerebellum       Date:  2004       Impact factor: 3.847

Review 2.  Modulation of NMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulating NMDA receptor function.

Authors:  Ana Sanchez-Perez; Marta Llansola; Omar Cauli; Vicente Felipo
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

3.  Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.

Authors:  Nupur Nag; Volga Tarlac; Elsdon Storey
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

4.  Depression of extra-cellular GABA and increase of NMDA-induced nitric oxide following acute intra-nuclear administration of alcohol in the cerebellar nuclei of the rat.

Authors:  Mario Manto; Marie-Aline Laute; Massimo Pandolfo
Journal:  Cerebellum       Date:  2005       Impact factor: 3.648

5.  Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia.

Authors:  Hao Wang; Jonathan Norton; Lin Xu; Nicholas DeMartinis; Rohini Sen; Ankit Shah; Jennifer Farmer; David Lynch
Journal:  Ann Clin Transl Neurol       Date:  2021-05-20       Impact factor: 4.511

Review 6.  D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.

Authors:  Sebastian Schade; Walter Paulus
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.